Related Experiment Video
Updated: Apr 28, 2026

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses
Published on: September 7, 2022
Rational Design and Screening of Chemically Modified Anti-SARS-CoV-2 siRNA
Zihui Cheng1,2,3, Ying Cai1,2, Enhua Zhang4
1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201210, China.
None:
To realize the therapeutic potential of RNA interference against severe acute respiratory syndrome coronavirus 2, strategic chemical modifications are crucial for enhancing the siRNA stability and potency. In this study, 200 siRNAs were screened to identify effective candidates that targeted the highly conserved RNA-dependent RNA polymerase gene and identified VS-38m as a lead compound. Building on this scaffold, we systematically evaluated a series of modification patterns by introducing 2'-fluoro (2'-F) and 2'-O-methyl (2'-OMe) substitutions at specific positions on both the guide and sense strands. To further improve guide strand selection, asymmetric 3'-end modifications, including glycol nucleic acid, threose nucleic acid, and unlocked nucleic acid, were incorporated at the 3' end of the sense strand. The optimized siRNA VS-159m102 demonstrated superior gene-silencing efficacy at picomolar concentrations, along with reduced cytotoxicity and improved serum stability. Our findings on optimal modification patterns provide valuable insights for the future development and application of siRNA therapeutics.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

